Oramed Pharmaceuticals management opened trading this morning on the occasion of its TASE dual listing.
The company is developing an oral Insulin capsule, as well as other kinds of oral capsules, to transform injectable treatments into oral therapies. The company completed in 2016 the Phase II trials of its flagship product.
Oramed's current market capitalization is approx. $109 million.
Nadav Kidron, Oramed CEO, Director and Founder: "We believe dual-listing on TASE will provide many benefits to our Company and our shareholders. An expanded investor pool including Israel’s largest institutional investors, eligibility for being included in Israel’s index funds, and expanded trading days and hours to serve global investors, especially those in Europe and Asia, are all factors that we believe will contribute to superior trading, liquidity and valuation for Oramed stock.”
Hani Shitrit Bach, TASE SVP and Head of Listing & Economics Department: "Oramed is joining 64 companies, which are dual traded in Tel Aviv and New York or Europe. It also joins 60 Biomed companies traded in TASE.
By dual listing in Tel Aviv, Oramed enjoys many benefits. The company will enjoy much exposure to the Israeli market, and it will join the TA-SME150, the TA-SME60, the TA-Global BlueTech, and the TA-Biomed indices starting September 2017."
Pictured, from right to left:
Nadav Kidron, Oramed CEO, Director and Co-Founder; Dr. Miriam Kidron, Oramed R&D Director, Director and Co-Founder; Josh Hexter, Oramed Vice President of Business Development; Yifar Zommer, Oramed CFO; Aviad Friedman, Director at Oramed; and Hani Shitrit Bach, TASE SVP and Head of Listing & Economics Department.
Photographer: Guy Assayag (photo free-of-charge)
